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The biological activity of some long hydrocarbon keto-diols (and their phosphate esters) and
acids, has been correlated with their lipohilicity. IC50 values of the hepatocyte lipid synthesis
inhibition (in vitro) were used to measure biological activity; lipohilicities were calculated by
employing a 3D molecular size approach implemented in a QLogP software package. Although
no quantitative correlation was observed, the results of the study might be significant for in
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INTRODUCTION
The ability of a drug to penetrate various biological mem-
branes, tissues and barriers is a primary factor in control-
ling the interaction of drugs with biological systems. In
quantitative structure activity relationship models (QSAR)
in which physicochemical parameters of drugs are corre-
lated with biological activities, lipophilicity (partition
coefficients, chromatographic parameters) has a major
role. Other important parameters are polarizability, elec-
tronic and steric parameters, molecular weight, geome-
try, conformational entropies etc.
Lipophilicity is defined by the partitioning of a com-
pound between an aqueous and a nonaqueous phase. The
logarithm of the partition coefficient between 1-octanol
and water (log P) is a physicochemical property widely
used in medicinal chemistry. Theoretically calculated log
P values, by using sophisticated quantum chemistry and
molecular modeling procedures, are in some instances,
particularly in congener series, quite well correlated with
experimental partition coefficients.
Correlation of biological activity of some compounds
experimented as cardiovascular agents with their ability
to penetrate biological membranes, as reflected by their
lipophilicities, is presented herein.
The compounds included in this study are long hydro-
carbon chain keto-diols (and their phosphates) and acids.
The symmetrical or unsymmetrical side chains connected
to the central ketone functionality vary both in their lengths
(3 to 5 carbon atoms) and in the nature of the attached
geminal modifying groups (methyl, phenyl or substituted
phenyl) (Chart 1, Series I). For comparison representa-
tives of a second series of compounds that possess a
central ether functionality (Chart 2, Series II), have been
included in this study.
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These compounds have promising biological activ-
ity both in vitro and in vivo. Indeed, when administered
orally to experiment animals models of disease, they re-
duced levels of low density lipoproteins (LDL) and,
more importantly, also increased levels of high density
lipoproteins (HDL). These are changes that are known to
correlate with reducing the risk of cardiovascular disease
in humans. In this series of compounds the biological ac-
tivity varies with structural modifications, thus influenc-
ing lipophilicities and other physicochemical properties.
There is a strong possibility that the activity in the
series of compounds can be correlated with their ability
to penetrate biological membranes, which is dependent
on lipophilicity factors. This study is designed to assess
the correlation between the theoretically calculated
lipophilicity of the compounds and their biological ac-
tivity, and to assess the utility of the theoretically calcu-
lated log P to predict biological activity.
EXPERIMENTAL
Synthesis
Compounds presented in Charts 1 and 2 were synthesized
by conventional procedures as described elsewhere.1–3
Biological Activities
Compounds were tested for inhibition of lipid synthesis in
primary cultures of rat hepatocytes. Male Sprague-Dawley
rats were anesthetized with intraperitoneal injection of so-
dium pentobarbital. Livers were perfused and cells were
isolated using a modified method of Ulrich et al.4
Hepatocytes were plated in medium (DMEM supplemented
to 20 % fetal bovine serum, 14 mmol dm–3, 0.2 % bovine
albumin, 2 mmol dm–3 L-glutamine, 1X MEM non-essen-
tial amino acids, 100 mmol dm–3 insulin, 100 µg ml–1 dexa-
methasone and 20 µg ml–1 gentamicin) at a density of 3.0 x
104 cell/well on collagen-coated 96-well plastic dishes.
Cells were allowed to attach for 3–4 hours in a humidified
environment (37 °C; 95 % air, 5 % CO2) prior to exchang-
ing media with serum and dexamethasone free-DMEM sup-
plemented as described above. Hepatocytes were incubated
in 0.2 mL/well of DMEM medium overnight prior to treat-
ment.
To test the effect of various compounds on the synthesis
rates of total lipids, the monolayer cultures were exposed to
1, 3, 10, 30, 100, or 300 mol dm–3 of compound in DMEM
containing 1 µCi ml–1 14C-acetate and 0.1 % DMSO. Con-
trol cells were exposed to the same media lacking test com-
pounds. Metabolic labeling with 14C-acetate continued for
4 h at 37 °C. After labeling, cells were washed twice with
ice-cold PBS and frozen. Incorporation of 14C-acetate into
organic soluble products was assessed using MicroScint
E) and counted on a Topcount®. The 50 % inhibitor con-
centration (IC50) values are derived from statistical model-
ing of the data and are indicated in Table I.
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A 3D molecular size approach developed by Bodor and Buch-
wald5 implemented in the QLogP software package has been
used to calculate lipophilicities. The latest version (2.01 beta),
proven to give fairly accurate results, as compared to experi-
mental determinations, was employed. This fully comput-
erized model employs molecular mechanics (Alchemy II;
Tripos Assoc., St Louis, MO) for optimization of molecular
structures. Van der Waals radii were used to calculate mo-
lecular volumes. The method has been described in detail e.g.
as applied to predict octanol-water partition of peptides6 or
to determine QLogP as theoretical descriptor for a quantita-
tive structure-toxicity relationship of pollutants.7
RESULTS AND DISCUSSION
Calculated QLogP and experimental biological activities
in Series I–II are presented in Table I. Formulas and mo-
lecular weights of the examined compounds were in-
cluded as well.
All calculated log P values are for neutral forms of
compounds. While for alcohols the results should be
fairly accurate, in the case of ionizable compounds
(carboxylic acids, phosphates) the values describe a case
in which the aqueous phase represents a buffer with a
pH at which the compound is not neutralized, such as a
pH < 2 for carboxylic acids. If a buffer close to the neu-
tral as the physiological pH (= 7.4) is used, an apparent
partition coefficient is calculated (log D). Accordingly
an ionization correction should be used that is dependent
on the strength (pKa) of acids. This correction leads to
lower log P.
As expected, lipophilicity increases with the length
of the alkyl chains, as for example in the series of diols:
1 (n = n' = 3; QLogP = 3.11) < 9 (n = 3; n' = 4; QLogP =
3.55) < 2 (n = n' = 4; QLogP = 3.98) < 11 (n = 4; n' = 5;
QLogP = 4.43) < 4 (n = n' = 5; QLogP = 4.88) < 12 (n =
n' = 6; QLogP = 5.99) < 14 (n = n' = 7; QLogP = 7.09).
Terminal functional groups increase lipophilicity in
the order phosphate < alcohol < carboxyl, for example: 3
(phosphate, QLogP = 0.55) < 2 (hydroxyl, QLogP =
3.98) < 6 (carboxyl, QLogP = 4.05). The lipophilicity of
alcohols and corresponding carboxylic acid is almost
identical; however considering pKa corrections, in real-
ity alcohols are more lipophilic.
The modifying groups increase lipophilicity in the or-
der of their size and lipophilicity: methyl, phenyl < methyl-
phenyl < isobutylphenyl, as illustrated by the series: 2 (bis
dimethyl; QLogP = 3.98) < 21 (dimethyl, methylphenyl;
QLogP = 5.42) < 15 (bis methyl, methylphenyl; QLogP
= 6.87) < 17 (bis methyl, (methyl)phenyl; QLogP = 7.76)
< 19 (bis methyl, (isobutyl)phenyl; QLogP = 10.46).
The central moiety does not modify significantly lipo-
philicity in the examined series as it only slightly increases
from: C–O–C (ether) to C=O (ketone), e.g. 28 (ether;
QLogP = 3.76) < 2 (keto; QLogP = 3.98).
Calculated QLogP values have been compared with
IC50 values of the hepatocyte lipid synthesis inhibition.
The results are indicated in Table I.
Experimentally determined biological activity indi-
cated a certain dependence on lipophilicity, although no
linear correlation was registered (Figure 1). In the series
of aliphatic keto-diols 1, 2, 4, 9, 11, 12, 14, while the
least lipophilic members of the series (1 and 9) mani-
fested little potency, the other compounds having calcu-
lated QLogP between 4 and 7 were quite active. The
most active component of the series was the asymmetric
diol 11, having QLogP = 4.43. The series of keto-dicar-
boxylic acids with lipophilicities increasing in the series
8 < 6 < 7 < 13 indicated relatively modest activity, ex-
cept for compound 6 (QLogP = 4.05) that proved to be
quite potent. As expected, phosphates 3 and 5, belonging
to the aliphatic keto series were not biologically active.
The series containing bulky terminal groups (15–24)
having large molecular weights and large values of cal-
culated QLogP (from 6 to 10.5) proved to be inactive.
The lack of biological activity was not unexpected. Indeed,
while lipophilic compounds penetrate various membra-
nes, including cellular membranes as well as tissues with
high lipoid content, hydrophilic compounds do not pene-
trate lipoidal membranes and are found mainly extra cel-
lularly. However, there is a limit for a proper lipophilicity.
According to the »rule of 5« of Lipinski,8 lipohilicities
higher than 5 (as well as molecular weights higher than
500) are not advantageous, as they lead to a decrease in
bioavailability. This rule although not unanimously ac-
cepted, is quite frequently applied in drug design. It is
known that compounds with very high log P as those with
very low lipophilicity do not have good bio-availability
as they cannot cross hydrophilic and lipophilic barriers,
respectively. Molecules with intermediary lipophilicity
have better chances to arrive at the receptor site.
While lipophilicity of alcohols and carboxylic acids
guarantee their access to the desired pharmacological
targets, phosphates appear to be too hydrophilic in this
purpose. Accordingly, in vitro studies of phosphates in-
dicate little activity. The situation might be different in
vivo, as phosphates can be hydrolyzed enzymatically by
(alkaline or acid) phosphatases. Phosphates should act as
prodrugs, the active agent being the corresponding alco-
hol released in vivo. Situated on the other extreme, com-
pounds like 15–23 were not expected to be active due to
their high lipophilicity and molecular weights. The ex-
perimental results confirmed these predictions. Interest-
ingly, the asymmetric compound 24 having only one ter-
minal phenyl group (QLogP = 5.42) proved to be the
most active compound of the whole series.
Compounds belonging to series 27–30 indicated that
modifying the central region (carbonyl group with ether
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1 C15H30O3 258.40 3.11 31
2 C17H34O3 286.45 3.98 4.4
3 C17H36O9P2 446.41 0.55 16
4 C19H38O3 314.51 4.88 4.2
5 C19H40O9P2 474.47 1.44 35
6 C17H30O5 314.42 4.05 2.8
7 C19H34O5 342.47 4.94 32
8 C16H28O5 300.39 3.61 8.3
9 C16H23O3 272.43 3.55 9.2
10 C18H32O5 328.45 4.49 3.2
11 C18H32O3 300.48 4.43 2.4
12 C21H42O3 342.56 5.99 4.1
13 C21H38O5 370.52 6.26 9.5
14 C21H38O5 370.52 7.09 4.8
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15 C25H30O5 410.51 6.08 Not active
16 C25H34O3 382.54 5.97 227
17 C27H34O5 438.56 6.92 Not active
18 C27H38O3 410.60 6.87 145
19 C29H38O5 466.62 7.84 195
20 C29H42O3 438.65 7.76 130
21 C35H50O5 550.78 10.47 106
22 C35H54O3 522.81 10.46 Not active
23 C29H42O3 438.65 7.77 103
24 C22H36O3 348.52 5.42 1.1
25 C23H26O5 382.46 5.89 Not reported
26 C23H30O3 30 5.85 52
27 C16H34O3 274.44 3.76 10
28 C18H38O3 302.50 4.64 3.8
29 C16H36O9P2 434.40 0.32 40
30 C18H40O9P2 462.46 1.20 25.5
(cont.)
moiety) does not influence dramatically the activity. In-
deed, while phosphates are less active, the two diols,
particularly compound 28 having QLogP = 4.64 proved
to be biopotent.
In conclusion, calculated QLogP values have been cor-
related with IC50 values of the hepatocyte lipid synthesis
inhibition. Compounds with the best in vitro biological
activity had QLogP values in the range 4–7. However,
compounds with QLogP higher than 5 might not be ap-
propriate candidates for in vivo experiments. Structural
features are important for activity. It appears that in or-
der to be active, both side chains connected to the central
atom(s) of a compound should consist of at least four car-
bon atoms. While the environment at the center of mole-
cules does not seem to have much influence over activity,
at least in the examined structures, bulky linkers and ter-
minal groups tend to reduce biological activity. The ac-
tivity of compound 24 is of interest and will be better
examined. While alcohols and carboxylic acids having the
proper structures and required lipophilicity are generally
potent, phosphates do not have much in vitro activity;
however, they might be experimented as water soluble
prodrugs of the alcohol type combinations. In the pres-
ent study, no quantitative correlation between calculated
lipophilicity and experimental biological activity was
observed. The situation might be different in vivo, where
lipophilicity becomes more important. Indeed, while in
vitro the only existing barrier is the cell membrane, in
vivo a drug has to surpass several biological barriers to
reach its target and to assure a proper bioavailability.
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SA@ETAK
Lipofilni parametri i bioaktivnost niza spojeva s mogu}om kardiovaskularnom primjenom
Emil Pop, Daniela C. Oniciu, Michael E. Pape, Clay T. Cramer i Jean-Louis H. Dasseux
Korelirana je bioaktivnost nekih acikli~kih dugolan~anih keto-diola (i njihovih fosfatnih estera) i kiselina s
lipofilno{}u. IC50 vrijednosti inhibicije hepatocitne lipidne sinteze (in vitro) upotrebljene su kao mjera bioaktiv-
nosti razmatranih spojeva, a lipofilnost je izra~unana pomo}u programskoga paketa QlogP u koji je implementi-
ran ra~unski postupak koji uzima u obzir 3D strukturu molekula. Premda autori nisu dobili kvantitativnu kore-
laciju izme|u bioaktivnosti i lipofilnosti razmatranih spojeva, njihovi rezultati mogu se upotrijebiti u in vivo
aplikaciji tih spojeva kao mogu}i kardiovaskularni agensi.
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Figure 1. IC50 values versus QLogP values.
